Want to see KPRX full AI Analyst Report?
KPRX Stock Chart & Stats
$1.91
-$0.13(-3.22%)
At close: 4:00 PM EST
$1.91
-$0.13(-3.22%)
Day’s Range― - ―
52-Week Range$1.76 - $3.29
Previous CloseN/A
Volume13.46K
Average Volume (3M)36.18K
Market Cap
$11.66M
Enterprise Value$808.31K
Total Cash (Recent Filing)$13.87M
Total Debt (Recent Filing)$373.59K
Price to Earnings (P/E)―
Beta1.18
Next Earnings
Aug 07, 2026EPS Estimate
-0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.66
Shares Outstanding4,431,940
10 Day Avg. Volume38,148
30 Day Avg. Volume36,176
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.51
Price to Sales (P/S)0.00
P/FCF Ratio-0.81
Enterprise Value/Market Cap0.07
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-19.26
Enterprise Value/Ebitda-0.07
Forecast
1Y Price Target
$12.00Price Target Upside528.27% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-2.89
Revenue Forecast (FY)$1.50M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Limited DebtVery low debt-to-equity (~0.03) materially reduces solvency and interest-rate pressure, giving the company financial flexibility to prioritize R&D and trial execution. This durable capital structure lowers default risk and preserves optionality while cash burn continues.
Platform Diversification Into CNSKIO-300 data extending activity from retinal hyperactivity into a CNS epilepsy model meaningfully broadens the platform's addressable indications. Structural expansion beyond ophthalmology increases long-term partnership, licensing, and pipeline optionality versus a single-indication biotech.
Committed Near-term Financing With UpsideThe $5M at-the-market placement provides immediate runway to fund trials and operations, while milestone/exercise-linked warrants create contingent capital without immediate dilution. Registered resale commitment also signals institutional investor support and improves financing optionality.
Bears Say
Zero Revenue And Sustained Cash BurnThe absence of revenue and persistent negative operating and free cash flow (~$10M+ TTM) mean the business relies on external funding to sustain clinical programs. This structural cash burn raises execution and financing risk over the coming months absent durable revenue or large financing.
Eroding Equity And Asset BaseMaterial declines in equity and assets over recent periods signal the capital base is being consumed by losses. A thinner balance sheet reduces the company's buffer against trial setbacks and increases the likelihood and cost of future financings, structurally raising dilution or insolvency risk.
Senior Development Leadership TurnoverDeparture of the CDO creates durable execution risk for ongoing Phase 2 programs (ABACUS-2, KLARITY). Replacing a senior clinical leader can slow enrollment, regulatory interactions, and trial oversight, increasing the probability of operational delays or higher external CRO costs.
Kiora Pharmaceuticals News
KPRX FAQ
What was Kiora Pharmaceuticals’s price range in the past 12 months?
Kiora Pharmaceuticals lowest stock price was $1.76 and its highest was $3.29 in the past 12 months.
What is Kiora Pharmaceuticals’s market cap?
Kiora Pharmaceuticals’s market cap is $11.66M.
When is Kiora Pharmaceuticals’s upcoming earnings report date?
Kiora Pharmaceuticals’s upcoming earnings report date is Aug 07, 2026 which is in 35 days.
How were Kiora Pharmaceuticals’s earnings last quarter?
Kiora Pharmaceuticals released its earnings results on May 08, 2026. The company reported -$0.58 earnings per share for the quarter, beating the consensus estimate of -$0.71 by $0.13.
Is Kiora Pharmaceuticals overvalued?
According to Wall Street analysts Kiora Pharmaceuticals’s price is currently Undervalued.
Does Kiora Pharmaceuticals pay dividends?
Kiora Pharmaceuticals does not currently pay dividends.
What is Kiora Pharmaceuticals’s EPS estimate?
Kiora Pharmaceuticals’s EPS estimate is -0.47.
How many shares outstanding does Kiora Pharmaceuticals have?
Kiora Pharmaceuticals has 4,431,940 shares outstanding.
What happened to Kiora Pharmaceuticals’s price movement after its last earnings report?
Kiora Pharmaceuticals reported an EPS of -$0.58 in its last earnings report, beating expectations of -$0.71. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Kiora Pharmaceuticals?
Currently, no hedge funds are holding shares in KPRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Kiora Pharmaceuticals
Kiora Pharmaceuticals, Inc., a specialty pharmaceutical firm operating at the clinical stage, is dedicated to the creation and commercialization of treatments for various ophthalmic conditions across the United States. Its flagship therapeutic candidate, KIO-301, is a groundbreaking small molecule undergoing Phase 1 clinical trials. This innovative "photoswitch" aims to revitalize vision in individuals suffering from both inherited and age-related forms of retinal degeneration. The company's pipeline also includes KIO-101, an eye drop currently in Phase 2 trials for addressing the ocular manifestations of rheumatoid arthritis, as well as non-infectious posterior uveitis. Furthermore, Kiora is advancing KIO-201, another eye drop, which is in Phase 3 clinical trials, designed to facilitate corneal wound healing following PRK surgery. Established in 1998, the company adopted its current name in November 2021, having previously operated as Eyegate Pharmaceuticals, Inc. Kiora Pharmaceuticals maintains its corporate headquarters in Salt Lake City, Utah.
KPRX Stock 12 Month Forecast
Average Price Target
$12.00
▲(528.27% Upside)
Technical Analysis
Ownership Overview
2.99% Insiders
1.05% Mutual Funds
4.02% Other Institutional Investors
91.38% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---